Univariate analysis for serologic response rate in patients with CLL
| Variable . | Serologic response, N (%) . | . | . | . | . | |
|---|---|---|---|---|---|---|
| Positive . | Negative . | Total . | P . | OR . | 95% CI . | |
| Age in time of vaccination | ||||||
| ≤65 y | 26 (52.0) | 24 (48.0) | 50 | .031 | 2.09 | 1.01-4.32 |
| >65 y | 40 (34.2) | 77 (65.8) | 117 | |||
| Sex | ||||||
| Female | 30 (54.5) | 25 (45.5) | 55 | .005 | 2.53 | 1.24-5.18 |
| Male | 36 (32.1) | 76 (67.9) | 112 | |||
| Treatment status (detailed) | ||||||
| Treatment-naive | 32 (55.2) | 26 (44.8) | 58 | <.001 | 1 | |
| On-therapy | 12 (16.0) | 63 (84.0) | 75 | 0.16 | 0.07-0.35 | |
| Off-therapy in remission (CR or PR) | 19 (79.2) | 5 (20.8) | 24 | 3.01 | 1.02-9.40 | |
| Off-therapy in relapse | 3 (30.0) | 7 (70.0) | 10 | 0.35 | 0.08-1.48 | |
| Binet stage | ||||||
| A | 29 (67.4) | 14 (32.6) | 43 | .001 | 6.21 | 1.80-22.96 |
| B or C | 6 (24.0) | 18 (75.0) | 24 | |||
| IGHV | ||||||
| Mutated | 29 (47.5) | 32 (52.5) | 61 | .005 | 3.04 | 1.31-7.21 |
| Unmutated | 14 (23.0) | 47 (77.0) | 61 | |||
| FISH test | ||||||
| Normal | 9 (45.0) | 11 (55.0) | 20 | .061 | 1 | |
| del(13q) | 16 (41.0) | 23 (59.0) | 39 | 0.85 | 0.28-2.52 | |
| Trisomy 12 | 6 (37.5) | 10 (62.5) | 16 | 0.73 | 0.19-2.80 | |
| del(11q) | 11 (35.5) | 20 (64.5) | 31 | 0.67 | 0.21-2.12 | |
| del(17p) | 1 (5.30) | 18 (94.7) | 19 | 0.07 | 0.01-0.61 | |
| β2-microglobulin | ||||||
| ≤3.5 mg/L | 43 (47.8) | 47 (52.2) | 90 | .004 | 4.80 | 1.44-20.54 |
| >3.5 mg/L | 4 (16.0) | 21 (84.0) | 25 | |||
| Current treatment status | ||||||
| Untreated | 54 (58.7) | 38 (41.3) | 92 | <.001 | 7.46 | 3.38-17.14 |
| Treated | 12 (16.0) | 63 (84.0) | 75 | |||
| Treatment protocol | ||||||
| BTKi | 8 (16.0) | 42 (84.0) | 50 | .601 | 1 | |
| Venetoclax ± anti-CD20 antibody | 3 (13.6) | 19 (86.4) | 22 | 0.82 | 0.20-3.48 | |
| Others | 1 (33.3) | 2 (66.7) | 3 | |||
| Anti-CD20 (last treatment) | ||||||
| At least 12 mo later | 25 (45.5) | 30 (54.6) | 55 | <.001 | 37.6 | 2.2-651.3 |
| Within <12 mo | 0 (0.0) | 22 (100.0) | 22 | |||
| Serum IgG level | ||||||
| ≥550 mg/dL | 53 (49.1) | 55 (50.1) | 108 | <.001 | 5.37 | 2.11-15.34 |
| <550 mg/dL | 7 (14.6) | 39 (85.4) | 46 | |||
| Serum IgM level | ||||||
| ≥40 mg/dL | 39 (59.1) | 27 (40.9) | 66 | <.001 | 4.84 | 2.27-10.37 |
| <40 mg/dL | 20 (23.0) | 67 (77.0) | 87 | |||
| Serum IgA level | ||||||
| ≥80 mg/dL | 42 (34.5) | 47 (54.5) | 89 | .012 | 2.42 | 1.15-5.19 |
| <80 mg/dL | 17 (24.5) | 46 (38.5) | 63 | |||
| Variable . | Serologic response, N (%) . | . | . | . | . | |
|---|---|---|---|---|---|---|
| Positive . | Negative . | Total . | P . | OR . | 95% CI . | |
| Age in time of vaccination | ||||||
| ≤65 y | 26 (52.0) | 24 (48.0) | 50 | .031 | 2.09 | 1.01-4.32 |
| >65 y | 40 (34.2) | 77 (65.8) | 117 | |||
| Sex | ||||||
| Female | 30 (54.5) | 25 (45.5) | 55 | .005 | 2.53 | 1.24-5.18 |
| Male | 36 (32.1) | 76 (67.9) | 112 | |||
| Treatment status (detailed) | ||||||
| Treatment-naive | 32 (55.2) | 26 (44.8) | 58 | <.001 | 1 | |
| On-therapy | 12 (16.0) | 63 (84.0) | 75 | 0.16 | 0.07-0.35 | |
| Off-therapy in remission (CR or PR) | 19 (79.2) | 5 (20.8) | 24 | 3.01 | 1.02-9.40 | |
| Off-therapy in relapse | 3 (30.0) | 7 (70.0) | 10 | 0.35 | 0.08-1.48 | |
| Binet stage | ||||||
| A | 29 (67.4) | 14 (32.6) | 43 | .001 | 6.21 | 1.80-22.96 |
| B or C | 6 (24.0) | 18 (75.0) | 24 | |||
| IGHV | ||||||
| Mutated | 29 (47.5) | 32 (52.5) | 61 | .005 | 3.04 | 1.31-7.21 |
| Unmutated | 14 (23.0) | 47 (77.0) | 61 | |||
| FISH test | ||||||
| Normal | 9 (45.0) | 11 (55.0) | 20 | .061 | 1 | |
| del(13q) | 16 (41.0) | 23 (59.0) | 39 | 0.85 | 0.28-2.52 | |
| Trisomy 12 | 6 (37.5) | 10 (62.5) | 16 | 0.73 | 0.19-2.80 | |
| del(11q) | 11 (35.5) | 20 (64.5) | 31 | 0.67 | 0.21-2.12 | |
| del(17p) | 1 (5.30) | 18 (94.7) | 19 | 0.07 | 0.01-0.61 | |
| β2-microglobulin | ||||||
| ≤3.5 mg/L | 43 (47.8) | 47 (52.2) | 90 | .004 | 4.80 | 1.44-20.54 |
| >3.5 mg/L | 4 (16.0) | 21 (84.0) | 25 | |||
| Current treatment status | ||||||
| Untreated | 54 (58.7) | 38 (41.3) | 92 | <.001 | 7.46 | 3.38-17.14 |
| Treated | 12 (16.0) | 63 (84.0) | 75 | |||
| Treatment protocol | ||||||
| BTKi | 8 (16.0) | 42 (84.0) | 50 | .601 | 1 | |
| Venetoclax ± anti-CD20 antibody | 3 (13.6) | 19 (86.4) | 22 | 0.82 | 0.20-3.48 | |
| Others | 1 (33.3) | 2 (66.7) | 3 | |||
| Anti-CD20 (last treatment) | ||||||
| At least 12 mo later | 25 (45.5) | 30 (54.6) | 55 | <.001 | 37.6 | 2.2-651.3 |
| Within <12 mo | 0 (0.0) | 22 (100.0) | 22 | |||
| Serum IgG level | ||||||
| ≥550 mg/dL | 53 (49.1) | 55 (50.1) | 108 | <.001 | 5.37 | 2.11-15.34 |
| <550 mg/dL | 7 (14.6) | 39 (85.4) | 46 | |||
| Serum IgM level | ||||||
| ≥40 mg/dL | 39 (59.1) | 27 (40.9) | 66 | <.001 | 4.84 | 2.27-10.37 |
| <40 mg/dL | 20 (23.0) | 67 (77.0) | 87 | |||
| Serum IgA level | ||||||
| ≥80 mg/dL | 42 (34.5) | 47 (54.5) | 89 | .012 | 2.42 | 1.15-5.19 |
| <80 mg/dL | 17 (24.5) | 46 (38.5) | 63 | |||